Director David Weill Buys 1,336 Shares of TransMedics Group (TMDX)

gurufocus.com · 2026-09-15

David Weill, a Director at TransMedics Group Inc (TMDX), purchased 1,336 shares of the company on 2026-09-11, according to a recent SEC Filing. Following th

TickrTrends take: Director David Weill's purchase of 1,336 shares represents a show of confidence in TransMedics Group at current price levels, which aligns with TickrTrends' assessment that the Healthcare sector company is undervalued. Insider buying can signal that management believes the stock does not fully reflect the company's future prospects or asset value. Valuation-focused investors monitoring TMDX should track whether additional insider purchases or positive developments in the company's organ preservation technology business justify the undervalued rating.

Read the full story at gurufocus.com →